Table 1 Clinical and epidemiological data obtained for the 36 patients of collective A and B
From: Hospital outbreak caused by linezolid resistant Enterococcus faecium in Upper Austria
Characteristics | Â | Â |
|---|---|---|
Age, years, median (range) | 57 (22–91) |  |
Sex, n (%) | ||
 Male | 23 | 63.9 |
 Female | 13 | 36.1 |
Patient status, n (%) | ||
 Inpatient | 35 | 97.2 |
 Outpatient | 1 | 2.8 |
Transfer from other Hospital/LTCF, n (%) | ||
 Yes | 8 | 22.2 |
 No | 25 | 69.4 |
 Unknown | 3 | 8.3 |
LZD therapy (previous 28 days), n (%) | ||
 Yes | 10 | 27.8 |
 No | 25 | 69.4 |
 Unknown | 1 | 2.8 |
Duration of LZD therapy, days, median (range) | 9 (3–35) |  |
LREfm status, n (%) | ||
 Infection | 4 | 11.1 |
 Colonization | 30 | 83.3 |
 Unknown | 2 | 5.6 |
Duration of colonization, days, median (range) | 22 (3–245) |  |
Current antibiotic therapy, n (%) | ||
 Yes | 36 | 100.0 |
 No | 0 | 0.0 |
Hospital contact in previous year, n (%) | ||
 Yes | 31 | 86.1 |
 No | 2 | 5.6 |
 Unknown | 3 | 8.3 |
Underlying disease, n (%) | ||
 Hematology-Oncology | 25 | 69.4 |
 allogeneic SCT | 17 |  |
 autologous SCT | 3 |  |
 Trauma/orthopedic | 4 | 11.1 |
 Abdominal surgery/Pancreatitis | 4 | 11.1 |
 Other | 3 | 8.3 |
Immunocompromised, n (%) | ||
 Yes | 31 | 86.1 |
 No | 4 | 11.1 |
 Unknown | 1 | 2.8 |
Died during follow-up (until end of 2017), n (%) | ||
 Yes | 15 | 41.7 |
 No | 14 | 38.9 |
 Unknown | 7 | 19.4 |
Source material first LREfm isolate, n (%) | ||
 Stool | 18 | 50.0 |
 Urine | 9 | 25.0 |
 Swab (wound, throat, eye) | 7 | 19.4 |
 Blood culture | 1 | 2.8 |
 Catheter tip | 1 | 2.8 |
Source material secondary isolates, n (%) | ||
 Stool | 6 |  |
 Blood culture | 2 |  |
 Urine | 1 |  |
Screening sample, n (%) | ||
 Yes | 24 | 66.6 |
 No | 11 | 30.5 |
 Unknown | 1 | 2.77 |